SIGA Technologies, Inc. (SIGA) Company Overview

What does SIGA Technologies do?

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company listed on the Nasdaq Global Market under the ticker SIGA. Its business is unusually concentrated: the company develops, obtains regulatory approvals for, manufactures through third parties, and supplies medical countermeasures for serious infectious-disease threats. The centerpiece is TPOXX, or tecovirimat, an antiviral designed for orthopoxviruses. The official TPOXX product page describes oral and intravenous formulations approved in the United States for smallpox.

TPOXX is the core asset, not one segment among many

Unlike a diversified pharmaceutical company, SIGA has one dominant franchise. Oral TPOXX received U.S. Food and Drug Administration approval in 2018, and IV TPOXX received approval in 2022. The drug is procured mainly for preparedness rather than ordinary pharmacy demand. Governments buy treatment courses for strategic stockpiles, fund post-marketing or formulation work, and decide when to replenish inventories. That makes SIGA economically closer to a specialized government contractor with pharmaceutical regulatory risk than to a conventional prescription-drug seller.

Customer base and geographic reach

The U.S. Strategic National Stockpile remains the anchor customer, but international diversification has become strategically important. SIGA has sold product across multiple regions, obtained approvals or authorizations in Canada, Europe, the United Kingdom, and Japan, and signed a 2026 exclusive license arrangement with Hikma for the Middle East and North Africa. The model is therefore global in regulatory reach, even though annual revenue can still be dominated by one country and a few deliveries.

How does SIGA make money from TPOXX and government preparedness?

SIGA recognizes revenue primarily when treatment courses or related deliverables are accepted under fixed-price procurement contracts. It also earns research-and-development revenue when government-funded activities satisfy contract performance obligations. The 2025 Form 10-K shows why revenue should not be modeled as a smooth subscription stream: procurement orders, manufacturing milestones, acceptance dates, and exercised contract options determine the timing.

Procurement creates lumpy, milestone-driven revenue

The 2018 BARDA contract is central. At December 31, 2025, it contemplated up to approximately $630 million of payments, with most option value already exercised. The contract architecture created years of procurement and development work, but it also creates a transition risk: replenishment and future revenue require new awards, new orders, or additional international demand. A DCF should therefore separate contracted or highly visible deliveries from unawarded future stockpile demand.

Two revenue streams, one economic engine

Which strategic turning points created SIGA's current position?

SIGA's history matters because the current model is the result of a long conversion from antiviral development into a government-procurement franchise. Each turning point changed either regulatory credibility, addressable customers, formulation breadth, or the durability of the stockpile relationship.

From stockpile supplier to approved antiviral

1. 2013
   Oral TPOXX deliveries to the U.S. Strategic National Stockpile began, establishing an operating history with the core customer before commercial approval.
2. 2018
   The FDA approved oral TPOXX for smallpox, and SIGA entered the 19C BARDA contract. Regulatory validation and a long-duration procurement framework became the foundation of the franchise.
3. 2022
   The FDA approved IV TPOXX, while European authorization broadened tecovirimat's regional and orthopox positioning. Two formulations improved preparedness utility.
4. 2024
   Diem Nguyen became chief executive officer, and the company emphasized international access, new partnerships, and complementary infectious-disease opportunities.
5. 2025
   Japan approved TEPOXX for multiple orthopox indications, while BARDA added funding for pediatric development and manufacturing activities.
6. 2026
   SIGA secured an Asia-Pacific order and a MENA licensing partnership. At the same time, the EU removed the mpox indication after randomized trials did not show efficacy, preserving other authorized uses but narrowing the label.

Internationalization and formulation expansion

The strategy is now broader than simply waiting for another U.S. order. SIGA's corporate strategy emphasizes four priorities: continuing the U.S. Government partnership, advancing new indications and formulations, expanding global access through partners, and applying the company's capabilities to complementary therapeutic areas. The strategic tension is clear: diversification can reduce dependence on one buyer, but it requires regulatory spending, partner execution, and market development before orders become recurring.

What does the latest reported quarter show?

The latest official reporting period is the quarter ended March 31, 2026. The first-quarter 2026 results illustrate the defining feature of the business: a light delivery quarter can produce an accounting loss even when larger orders are scheduled for later periods.

Revenue timing dominates quarterly optics

Q1 2026 revenue fell from the prior-year quarter, while cost of sales rose because the quarter included IV TPOXX manufacturing and technology-transfer support. SG&A declined, but R&D expense increased as the company worked through European regulatory activity. Management expected more than $35 million of oral and IV product deliveries across the second and third quarters, including an Asia-Pacific order and U.S. stockpile deliveries. That planned cadence means Q1 alone is not a run-rate estimate.

Q1 balance sheet still absorbed planned cash use

Inventory increased to $56.5 million at March 31, 2026, consistent with manufacturing for expected deliveries. Accounts receivable was $4.5 million. The quarter-end balance sheet also included a $43.0 million dividend payable; the $0.60-per-share special dividend was paid on April 23. The detailed Q1 2026 Form 10-Q is therefore more informative than the income statement alone: cash was strong, but some of it had already been committed to shareholders and inventory.

How financially strong is SIGA between procurement cycles?

SIGA's financial strength comes from a debt-light balance sheet, meaningful cash, low fixed-asset needs, and the ability to generate substantial cash when large product orders are delivered. Its weakness is volatility. A single year can look highly profitable or merely adequate depending on the delivery mix and the timing of acceptance.

Profitability has been strong annually but not smooth

Cash balance and low capital intensity

What gives SIGA a competitive advantage in medical countermeasures?

SIGA's moat is a bundle of regulated capabilities rather than a consumer brand. TPOXX was the first FDA-approved antiviral for smallpox, a status confirmed by the FDA's smallpox preparedness materials. The company also has a long delivery record, two U.S.-approved formulations, a broad patent estate, and experience managing BARDA-funded development and procurement.

Regulatory approvals, patents, and government trust

Approval under the FDA's Animal Rule is difficult because efficacy must be established through relevant animal models when human efficacy trials are infeasible or unethical. That creates scientific, manufacturing, and regulatory barriers to entry. SIGA also disclosed 26 U.S. utility patents and 101 issued foreign patents across seven patent families as of February 20, 2026. Patents are not permanent, but the combination of know-how, validated manufacturing, stockpile integration, and regulatory history is harder to replicate than a single chemical claim.

Small size creates operating leverage and concentration

With 49 full-time employees, SIGA can generate meaningful earnings without maintaining a large commercial sales force or manufacturing footprint. That supports operating leverage when orders are delivered. However, reliance on contract manufacturers, specialist employees, and government relationships means disruptions can be disproportionately important. The same compact model that makes cash conversion attractive also reduces redundancy.

Who competes with SIGA, and where is its market position vulnerable?

Competition is not limited to another capsule. SIGA's filing names Emergent BioSolutions and Bavarian Nordic as medical-countermeasure competitors. The FDA also recognizes another approved smallpox therapeutic, Tembexa. Vaccines, antivirals, diagnostics, and other preparedness programs compete for finite government budgets, so even a differentiated drug can lose funding priority without losing clinical relevance.

Competition is broader than another smallpox pill

Buyer power is structurally high because national governments can determine requirements, delay procurement, negotiate fixed prices, and choose among preparedness priorities. Supplier power is also meaningful because SIGA depends on third-party manufacturers for raw materials, finished product, inventory management, and technology transfer. Barriers to entry are high, but so is customer concentration. In Porter's Five Forces terms, rivalry may be limited by the niche market, yet buyer and supplier leverage remain central.

Who owns SIGA stock and how does governance shape decisions?

SIGA has one class of common stock with one vote per share, but ownership is not dispersed evenly. The 2026 proxy statement reported 71,724,097 shares outstanding as of April 17, 2026 and identified two holders above 5%.

One-share-one-vote, but one holder has major influence

What management incentives emphasize

The board uses salary, annual cash incentives, and long-term equity awards. The proxy describes a pay-for-performance approach tied to strategic objectives and stockholder value. For researchers, the key governance question is whether incentives reward durable contract renewal, international diversification, regulatory execution, and prudent capital returns rather than simply one year's procurement-driven earnings.

Which growth drivers, risks, and KPIs matter most?

SIGA's opportunity set is credible but narrow. Growth can come from new U.S. procurement, recurring international orders, broader geographic registration, pediatric or post-exposure uses, and complementary medical countermeasures. The official announcement of TEPOXX approval in Japan shows how regional authorization can expand strategic relevance even before it produces large recurring revenue.

Growth catalysts

Risk and KPI dashboard

• Government concentration: future results depend heavily on U.S. and foreign procurement decisions, appropriations, and exercised options.
• Manufacturing dependence: third-party delays can shift revenue recognition and jeopardize contractual performance.
• Regulatory evidence: the EU mpox change proves that randomized clinical data can narrow a label and reduce commercial optionality.
• Patent and exclusivity: intellectual-property protection extends across several families, but key claims expire over time and alternatives exist.
• Capital allocation: recurring special dividends are attractive only if the company retains enough cash for inventory, development, and strategic flexibility.

What is the key analytical takeaway for valuation?

SIGA should not be valued by mechanically annualizing one quarter or applying a standard mature-pharma growth rate. The business is a portfolio of procurement probabilities layered on a strong cash position. Near-term value depends on known orders, delivery timing, product mix, and cash distributions. Long-term value depends on whether SIGA can replace the aging 19C BARDA opportunity set with a successor U.S. framework, convert international approvals into repeat orders, and protect the TPOXX franchise while funding additional uses or products.

DCF drivers

Comparable-company analysis is also difficult because SIGA combines pharmaceutical IP, government contracting, and national-security demand. A medical-countermeasure peer may have a broader portfolio but weaker product economics; a specialty pharmaceutical peer may have smoother prescriptions but more commercial infrastructure. The most defensible approach is to reconcile enterprise value with net cash, probability-weighted procurement cash flows, and explicit downside scenarios for contract gaps or regulatory setbacks.